Early Aspirin Withdrawal After PCI in ACS: NEO-MINDSET and TARGET Trials
Christopher Cannon, Senior Physician in the Cardiovascular Division at Brigham and Women’s Hospital, shared a post on LinkedIn:
”Keep the ASA for the first 12 months post ACS PCI.
The NEO-MINDSET trial found that early stopping and keeping P2Y12 monotherapy was NOT sufficient for efficacy.
Of note, another study published, the TARGET First looked at “low risk” STEMI patients and suggested one could stop ASA, but it appeared to have much less power with just 41 primary endpoints.
So – I will aim to keep DAPT for a year post PCI for ACS. (although sometimes one has to adapt for very high risk bleeding patients).”
Title: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes
Authors: Patricia O. Guimarães, Marcelo Franken, Caio A.M. Tavares, Murillo O. Antunes, Fabio S. Silveira, Pedro B. Andrade, Ricardo R. Bergo
Read the full article here.
Find more on Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH